Evaluation of haemodialysis as a protective technique for preventing high daily dose amikacin nephrotoxicity: an experimental study in an ovine model. - 2017
[en] Changes in pharmacokinetic parameters of critically ill patients make the treatment of infections challenging, particularly when multidrug-resistant bacteria are involved. The aim of this study was to evaluate the ability of haemodialysis to reduce the exposure to high dose amikacin and prevent nephrotoxicity. Amikacin 50 mg/kg was administered intravenously to six adult sheep once-daily for four days. The sheep were divided into two groups according to the implementation (group 1) or not (group 2) of haemodialysis. In group 1, haemodialysis was performed for 4 h, initiated 2 h after starting amikacin infusion. Amikacin area under the curve (AUC) and trough concentrations (Cmin) were used as markers of amikacin-induced nephrotoxicity. The median haemodialysis amikacin clearance was 2.14 L/h (35.6 mL/min), 14% of the mean total body clearance for 24 h. Haemodialysis reduced Cmin (group 1: 0.3 µg/mL [0.3-1.1]; group 2: 1.4 µg/mL [1.1-3.9]; P = 0.0003). A trend towards reduced AUC with haemodialysis was observed (group 1: 1450 µg/mL⋅h [1311-1716]; group 2: 3126 µg/mL⋅h [2581-3171]; P = 0.10). In conclusion, haemodialysis seems interesting in reducing AUC and Cmin after the injection of high-dose of amikacin, parameters known to be involved in its induced nephrotoxicity, in an experimental ovine model.
Disciplines :
Immunology & infectious disease
Author, co-author :
Pouzot-Nevoret, Céline; Soins Intensifs, Anesthésiologie et Médecine d'Urgence (SIAMU), Univ Lyon, VetAgro Sup, F-69280 Marcy l'Etoile, France, Univ Lyon, VetAgro Sup, APCSe, F-69280 Marcy l'Etoile, France. Electronic address: celine.pouzotnevoret@vetagro-sup.fr
Magnin, Mathieu; Soins Intensifs, Anesthésiologie et Médecine d'Urgence (SIAMU), Univ Lyon, VetAgro Sup, F-69280 Marcy l'Etoile, France, Univ Lyon, VetAgro Sup, APCSe, F-69280 Marcy l'Etoile, France
Allaouchiche, Bernard; Univ Lyon, VetAgro Sup, APCSe, F-69280 Marcy l'Etoile, France, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de Réanimation Médicale, 69310 Pierre-Bénite, France
Karam, G., Chastre, J., Wilcox, M.H., Vincent, J.-L., Antibiotic strategies in the era of multidrug resistance. Crit Care, 20, 2016, 136, 10.1186/s13054-016-1320-7.
Vincent, J.-L., Bassetti, M., François, B., Karam, G., Chastre, J., Torres, A., et al. Advances in antibiotic therapy in the critically ill. Crit Care, 20, 2016, 10.1186/s13054-016-1285-6.
Brasseur, A., Hites, M., Roisin, S., Cotton, F., Vincent, J.-L., De Backer, D., et al. A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study. J Antimicrob Chemother 71 (2016), 1386–1394, 10.1093/jac/dkv491.
Gálvez, R., Luengo, C., Cornejo, R., Kosche, J., Romero, C., Tobar, E., et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 38 (2011), 146–151, 10.1016/j.ijantimicag.2011.03.022.
Duszynska, W., Taccone, F.S., Hurkacz, M., Kowalska-Krochmal, B., Wiela-Hojeńska, A., Kübler, A., Therapeutic drug monitoring of amikacin in septic patients. Crit Care, 17, 2013, R165, 10.1186/cc12844.
Layeux, B., Taccone, F.S., Fagnoul, D., Vincent, J.-L., Jacobs, F., Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 54 (2010), 4939–4941, 10.1128/AAC.00441-10.
Taccone, F.S., Optimising amikacin regimens in septic patients. Int J Antimicrob Agents 39 (2012), 264–265, 10.1016/j.ijantimicag.2011.10.007.
Taccone, F.S., Laterre, P.-F., Spapen, H., Dugernier, T., Delattre, I., Layeux, B., et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care, 14, 2010, R53, 10.1186/cc8945.
Moore, R.D., Smith, C.R., Lietman, P.S., The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 149 (1984), 443–448.
EUCAST, European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table.pdf, 2016 [Accessed 7 October 2016].
Roger, C., Nucci, B., Louart, B., Friggeri, A., Knani, H., Evrard, A., et al. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother 71 (2016), 208–212, 10.1093/jac/dkv291.
Rybak, M.J., Abate, B.J., Kang, S.L., Ruffing, M.J., Lerner, S.A., Drusano, G.L., Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43 (1999), 1549–1555.
Mazzaferro, E.M., Ford, R.B., Section I—emergency care. Kirk and Bistner's Handbook of veterinary procedures and emergency treatment, 9th ed, 2012, W.B. Saunders, Saint Louis, 1–294.
Wellman, M.L., DiBartola, S.P., Kohn, C.W., Applied physiology of body fluids in dogs and cats. Fluid, electrolyte, and acid-base disorders in small animal practice, 4th ed, 2012, W.B. Saunders, Saint Louis, 2–25 Chapter 1.
Nawaz, M., Shah, B.H., Renal clearance of endogenous creatinine and urea in sheep during summer and winter. Res Vet Sci 36 (1984), 220–224.
ANSM, Mise au point sur le bon usage des aminosides administrés par voie injectable: gentamicine, tobramycine, nétilmicine, amikacine. 2011.
Thomas, M.E., Blaine, C., Dawnay, A., Devonald, M.A.J., Ftouh, S., Laing, C., et al. The definition of acute kidney injury and its use in practice. Kidney Int 87 (2015), 62–73, 10.1038/ki.2014.328.
Taccone, F.S., de Backer, D., Laterre, P.-F., Spapen, H., Dugernier, T., Delattre, I., et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 37 (2011), 531–535, 10.1016/j.ijantimicag.2011.01.026.
Neely, M., van Guilder, M., Yamada, W., Schumitzky, A., Jelliffe, R., Accurate detection of outliers and subpopulations with Pmetrics, a non-parametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34 (2012), 467–476, 10.1097/FTD.0b013e31825c4ba6.
Carli, S., Montesissa, C., Sonzogni, O., Madonna, M., Said-Faqi, A., Comparative pharmacokinetics of amikacin sulphate in calves and sheep. Res Vet Sci 48 (1990), 231–234.
Haritova, A., Lashev, L., Pharmacokinetics of amikacin in lactating sheep. Vet Res Commun 28 (2004), 429–435.
D'Arcy, D.M., Casey, E., Gowing, C.M., Donnelly, M.B., Corrigan, O.I., An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. BMC Pharmacol Toxicol, 13, 2012, 14, 10.1186/2050-6511-13-14.
Armstrong, D.K., Hodgman, T., Visconti, J.A., Reilley, T.E., Garner, W.L., Dasta, J.F., Hemodialysis of amikacin in critically ill patients. Crit Care Med 16 (1988), 517–520.
Tian, Q., Gomersall, C.D., Ip, M., Tan, P.E., Joynt, G.M., Choi, G.Y.S., Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agents Chemother 52 (2008), 1009–1013, 10.1128/AAC.00858-07.
Kerr, P.B., Argilés, A., Flavier, J.-L., Canaud, B., Mion, C.M., Comparison of hemodialysis and hemodiafiltration: a long-term longitudinal study. Kidney Int 41 (1992), 1035–1040, 10.1038/ki.1992.157.
Misset, B., Timsit, J.-F., Chevret, S., Renaud, B., Tamion, F., Carlet, J., A randomized cross-over comparison of the hemodynamic response to intermittent hemodialysis and continuous hemofiltration in ICU patients with acute renal failure. Intensive Care Med 22 (1996), 742–746, 10.1007/BF01709515.
Swartz, R.D., Messana, J.M., Orzol, S., Port, F.K., Comparing continuous hemofiltration with hemodialysis in patients with severe acute renal failure. Am J Kidney Dis 34 (1999), 424–432, 10.1016/S0272-6386(99)70068-5.
Nistor, I., Palmer, S.C., Craig, J.C., Saglimbene, V., Vecchio, M., Covic, A., et al. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. Cochrane Database Syst Rev(5), 2015, 10.1002/14651858.CD006258.pub2 CD006258.
Chater, K., Kellum, J.A., Continuous vs. intermittent hemodialysis: with which spin will my patient win?. Crit Care, 11, 2007, 313, 10.1186/cc6134.
Uehlinger, D.E., Jakob, S.M., Ferrari, P., Eichelberger, M., Huynh-Do, U., Marti, H.-P., et al. Comparison of continuous and intermittent renal replacement therapy for acute renal failure. Nephrol Dial Transplant 20 (2005), 1630–1637, 10.1093/ndt/gfh880.
Drusano, G.L., Ambrose, P.G., Bhavnani, S.M., Bertino, J.S., Nafziger, A.N., Louie, A., Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45 (2007), 753–760, 10.1086/520991.
Bertino, J.S., Booker, L.A., Franck, P.A., Jenkins, P.L., Franck, K.R., Nafziger, A.N., Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 167 (1993), 173–179.
Gauzit, R., Actualités en antibiothérapie—Aminosides toujours et encore: bon usage et suivi thérapeutique. Réanimation 20 (2010), 290–298, 10.1007/s13546-010-0106-1.
Palm, C.A., Segev, G., Cowgill, L.D., LeRoy, B.E., Kowalkowski, K.L., Kanakubo, K., et al. Urinary neutrophil gelatinase-associated lipocalin as a marker for identification of acute kidney injury and recovery in dogs with gentamicin-induced nephrotoxicity. J Vet Intern Med 30 (2016), 200–205, 10.1111/jvim.13819.
Aziz, M.A., Carlyle, S.S., Cardiovascular and respiratory effects of Xylazine in sheep. Zentralbl Veterinarmed A 25 (1978), 173–180, 10.1111/j.1439-0442.1978.tb00917.x.
Gómez de Segura, I.A., Tendillo, F.J., Mascías, A., Santos, M., Castillo-Olivares, J.L., Steffey, E.P., Actions of xylazine in young swine. Am J Vet Res 58 (1997), 99–102.
Dalen, R., van Vree, T.B., Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 16 (1990), S235–8, 10.1007/BF01709707.
